Patents by Inventor Mark X. Sliwkowski

Mark X. Sliwkowski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Use of heregulin as a growth factor
    Publication number: 20030199429
    Abstract: Ligands which bind to the HER2, HER3 and/or HER4 receptors are useful as normal epithelial cell growth factors.
    Type: Application
    Filed: June 3, 2003
    Publication date: October 23, 2003
    Applicant: Genentech, Inc.
    Inventors: Mark X. Sliwkowski, Jeffrey A. Kern
  • Tissue analysis and kits therefor
    Publication number: 20030152987
    Abstract: This invention relates to methods of analyzing a tissue sample from a subject. In particular, the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods.
    Type: Application
    Filed: January 23, 2003
    Publication date: August 14, 2003
    Applicant: GENENTECH, INC.
    Inventors: Robert L. Cohen, Mary Beth Gardiner, Mark X. Sliwkowski, Gregory T. Stelzer
  • Heregulin variants
    Publication number: 20030129688
    Abstract: The present invention provides heregulin variants that are capable of binding an ErbB receptor. Included in the invention are variants of human heregulins, and, in particular, variants of human heregulin-&bgr;1 having enhanced affinity for the ErbB-3 and ErbB-4 receptors. These variants include at least one amino acid substitution and can include further modifications. The invention also provides nucleic acid molecules encoding heregulin variants and related vectors, host cells, pharmaceutical compositions, and methods.
    Type: Application
    Filed: February 22, 2002
    Publication date: July 10, 2003
    Applicant: Genentech, Inc.
    Inventors: Marcus D. Ballinger, Jennifer T. Jones, Wayne J. Fairbrother, Mark X. Sliwkowski, James A. Wells
  • Tissue analysis and kits therefor
    Patent number: 6573043
    Abstract: This invention relates to methods of analyzing a tissue sample from a subject. In particular, the invention combines morphological staining and/or immunohistochemistry (IHC) with fluorescence in situ hybridization (FISH) within the same section of a tissue sample. The analysis can be automated or manual. The invention also relates to kits for use in the above methods.
    Type: Grant
    Filed: October 7, 1998
    Date of Patent: June 3, 2003
    Assignee: Genentech, Inc.
    Inventors: Robert L. Cohen, Mary Beth Gardiner, Mark X. Sliwkowski, Gregory T. Stelzer
  • Treatment with anti-ErbB2 antibodies
    Publication number: 20030086924
    Abstract: The present application describes methods for treating cancer with anti-ErbB2 antibodies, such as anti-ErbB2 antibodies that block ligand activation of an ErbB receptor.
    Type: Application
    Filed: October 10, 2002
    Publication date: May 8, 2003
    Applicant: GENENTECH, INC.
    Inventor: Mark X. Sliwkowski
  • ErbB4 antagonists
    Publication number: 20020119148
    Abstract: The present invention concerns methods and means for controlling excessive proliferation and/or migration of smooth muscle cells, and in particular for treating stenosis, by using antagonists of a native ErbB4 receptor. The invention further concerns a method for the identification of ErbB4 agonists and antagonists capable of inhibiting or enhancing the proliferation or migration of smooth muscle cells.
    Type: Application
    Filed: August 27, 2001
    Publication date: August 29, 2002
    Inventors: Mary E. Gerritsen, Mark X. Sliwkowski
  • Heregulin variants
    Patent number: 6387638
    Abstract: The present invention provides heregulin variants that are capable of binding an ErbB receptor. Included in the invention are variants of human heregulins, and, in particular, variants of human heregulin-&bgr;1 having enhanced affinity for the ErbB-3 and ErbB-4 receptors. These variants include at least one amino acid substitution and can include further modifications. The invention also provides nucleic acid molecules encoding heregulin variants and related vectors, host cells, pharmaceutical compositions, and methods.
    Type: Grant
    Filed: July 17, 1998
    Date of Patent: May 14, 2002
    Assignee: Genentech, Inc.
    Inventors: Marcus D. Ballinger, Jennifer T. Jones, Wayne J. Fairbrother, Mark X. Sliwkowski, James A. Wells
  • Use of heregulin as a growth factor
    Publication number: 20020042087
    Abstract: Ligands which bind to the HER2, HER3 and/or HER4 receptors are useful as normal epithelial cell growth factors.
    Type: Application
    Filed: February 23, 2001
    Publication date: April 11, 2002
    Inventors: Mark X. Sliwkowski, Jeffrey A. Kern
  • Use of heregulin as a growth factor
    Publication number: 20010023241
    Abstract: Ligands which bind to the HER2, HER3 and/or HER4 receptors are useful as normal epithelial cell growth factors.
    Type: Application
    Filed: February 2, 2001
    Publication date: September 20, 2001
    Inventors: Mark X. Sliwkowski, Jeffrey A. Kern
  • Heregulin variants
    Patent number: 6136558
    Abstract: The present invention provides heregulin variants that are capable of binding an ErbB receptor. Included in the invention are variants of human heregulins, and, in particular, variants of human heregulin-.beta.1 having enhanced affinity for the ErbB-3 and ErbB-4 receptors. These variants include at least one amino acid substitution and can include further modifications. The invention also provides nucleic acid molecules encoding heregulin variants and related vectors, host cells, pharmaceutical compositions, and methods.
    Type: Grant
    Filed: February 9, 1998
    Date of Patent: October 24, 2000
    Assignee: Genentech, Inc.
    Inventors: Marcus D. Ballinger, Jennifer T. Jones, Wayne J. Fairbrother, Mark X. Sliwkowski, James A. Wells